Key result
Enoxaparin regimens achieve target anti-factor Xa levels in only ~37% of obese hospitalized patients.
Why the study?
Does the choice of enoxaparin dosing regimen affect the achievement of therapeutic anti-factor Xa levels in obese adult patients?
Observational (n=52)
No
Does the choice of enoxaparin dosing regimen affect the achievement of therapeutic anti-factor Xa levels in obese adult patients?
Standard and capped enoxaparin dosing regimens frequently result in nontherapeutic anti-Xa levels in obese patients, suggesting a need for individualized dosing guided by anti-Xa monitoring.
Answers are grounded in this paper and cite their sources.
Therapeutic anti-Xa levels are infrequently achieved with current enoxaparin regimens in obese patients; this hypothesis-generating finding warrants randomized evaluation of monitoring-guided dosing.
Objectives: To evaluate the degree of anticoagulation achieved with different enoxaparin dosing regimens used in obese and morbidly obese patients in a hospital setting in Jordan. Methods: All obese adult patients who were prescribed enoxaparin for various indications were invited to participate in the study. The anti-factor Xa (anti-Xa) level was checked once after 4–6 hours of the third or fourth dose of enoxaparin (at steady state). Patients were followed daily to evaluate drug efficacy and safety through their hospital course. Results: Enoxaparin daily dose used for prophylaxis indications ranged from 0.3 to 0.85 mg/kg and from 0.31 to 2.25 mg/kg in case of certain treatment indications. Most participants who received enoxaparin for treatment indications (76.9%) were on capping dosing regimens, which was <1 mg/kg twice daily. On the other hand, most patients (88.5%) who received enoxaparin for prophylaxis indications were on a fixed 40 mg/d dose. Among the 52 patients who completed the study, 19 patients (36.5%) had therapeutic anti-Xa levels. The results showed no statistically significant associations between regimens that were used and achieving therapeutic anti-Xa level ( p >0.05). No bleeding events or thrombocytopenia were noticed, and there was one case of recurrent thrombosis. Conclusion: Enoxaparin dosing regimens that were used for obese patients varied based on prescribing physicians. Regardless of the regimen used, the majority of participants had nontherapeutic anti-Xa. Individualized dosing regimens based on anti-Xa levels are warranted for obese patients on enoxaparin.
No takes yet. Share an insight, caveat, or question.
Tahaineh et al. (2018) conducted an observational in Obesity requiring enoxaparin for venous thromboembolism prophylaxis or treatment (n=52). Enoxaparin vs. Different dosing regimens (capping vs non-capping) was evaluated on Achievement of therapeutic peak anti-factor Xa levels (p=>0.05). Enoxaparin dosing regimens achieved therapeutic peak anti-factor Xa levels in only 36.5% (19/52) of obese hospitalized patients, with no significant difference between regimens.
Synapse has enriched 10 related papers. Consider them for comparative context: